Iovance Biotherapeutics Inc
(HAM:2LB)
€
3.775
+0.090 (+2.44%)
Market Cap: 1.64 Bil
Enterprise Value: 1.41 Bil
PE Ratio: 0
PB Ratio: 2.54
GF Score: 44/100 Iovance Biotherapeutics Inc at JMP Group Hematology and Oncology Summit (Virtual) Transcript
Dec 07, 2021 / 06:40PM GMT
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst
And good afternoon, everyone. Welcome to the JMP Hematology & Oncology Summit. It's my pleasure to introduce the next presenting company, Iovance Biotherapeutics and here to talk about the company, Frederick Vogt, Interim CEO.
Questions & Answers
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst
Just jumping right into it. We've talked about the full interim CEO title. I would love to just start off by asking what's happening there? How is the search going? And are there any updates you could provide?
Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary
Sure. Yes. Right now, the search is going. We're -- the Board is committed to getting candidates in and talking with them and seeing if we can find the right person. I don't have any updates for you. This is one of those things where, at the very end, you
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot